Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Since then, we have seen tavapadon deliver positive phase 3 results in Parkinson's disease patients, and while I am not too ...

October 28, 202410:12 PM UTCUpdated ago Oct 28 (Reuters) - U.S. drugmaker AbbVie (ABBV.N), opens new tab said on Monday ... in an effort to build up its product pipeline. Aliada's ALIA-1758 ...

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The ...

and BUDAPEST, Hungary, Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery ... globally launched products such as cariprazine ...

One was to be a diversified medical products company – Abbott – and the other, a new researched-based global biopharmaceutical company – AbbVie. In January 2013, AbbVie was formed.

"This new agreement builds on years of successful partnership allowing Richter to further support AbbVie's global ambition ... competition from other products, difficulties inherent in the ...